Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A12066 | Pages: NA | Charts: NA | Tables: NA |
Mucormycosis, also known as zygomycosis, is a serious but rare fungal infection caused by a group of molds called mucormycetes. Furthermore, by inhaling fungal spores from the air can affect the lungs and sinuses. In addition, the fungus invades the skin through wounds such as cuts, scrape, burn, or other types of skin trauma. The fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. In addition, cases of mucormycosis have increased in COVID-19 patients who have received treatment. Steroid medicines are commonly used to manage the disease condition in these patients, and while they are effective in treating corona, they also weaken the immune system and raise blood sugar levels, making patients more susceptible to mucormycosis. Moreover, risk factors for developing mucormycosis include cancer, uncontrolled diabetes, neutropenia, and organ transplant. Mucormycosis symptoms vary depending on the extent of tissue involvement, but common symptoms include pain, fever, sinus pain, and organ cellulitis. The prognosis of mucormycosis is usually poor. It depends on various factors such as the patient's overall health & ability to respond to treatments, the speed of diagnosis, and the treatment provided. However, antifungal medications, such as amphotericin B, posaconazole, or isavuconazole are used to treat these infections.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment
drugs for COVID-19. This, in turn, is expected to have a significant impact on the mucormycosis market.
Top Impacting Factors
Increase in prevalence of fungal infections and rise in incidence of immunological diseases drive the growth of the mucormycosis market.
In addition, the exponential increase in cases of COVID-19 associated with mucormycosis in certain parts of the world is expected to be the major factor for the growth of the market during the forecast period.
Furthermore, increase in organ and bone marrow transplantation along with rise in hematological cancer cases and surge in diabetic patients since these have a weak immune system propel growth of the market.
The pandemic has an increased risk of mucormycosis, as COVID-19 patients are immune-compromised by the use of certain drugs used in viral treatment, which will further boost market growth.
Rise in use of steroids and other antiviral drugs will significantly impact the immune system of the patient. The steroid treatment increases the blood glucose levels in corona patients, which makes them more susceptible to mucormycosis, thereby supporting the growth of the market.
However, side effects of the drugs and presence of misbranded drugs hinder the growth of the market.
Market Trends
New Product Launches to Flourish the Market
In 2020,Pfizer Inc. in association with its partner Basilea Pharmaceutica Ltd., launched Cresemba (isavuconazole). The drug is used in mucormycosis and invasive aspergillosis.
In May 2021, TLC Pharma, a clinical-stage specialty pharmaceutical company, received approval for the New Drug Application (NDA) for Amphotericin B liposome injection (AmphoTLC), form the Central Drugs Standard Control Organization (CDSCO) of India. The drug can be used in the treatment of fungal infections including mucormycosis infections.
In June 2021, Celon Laboratories launched an alternative drug, Amphotericin B Emulsion for the treatment of mucormycosis.
Increase in Incidences of Mucormycosis
Rise in cases of mucormycosis in COVID-19 affected countries, especially in India notably contributes toward the market growth. In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment.
In the U.S. alone, more than 33 million people are affected by the disease till now. India is facing the worst second wave where 4, 00,000 cases are detected every day, which is the highest number of cases for any country from the beginning of the pandemic. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe which will further influence the market growth.
Key Benefits of the Report
Questions Answered in the Mucormycosis Market Report
Key Market Segments
Key Market Players